Updated PFS Results Now Available
The latest data for SARCLISA + Kd are ready to view
Kd=carfilzomib and dexamethasone; PFS=progression-free survival.

See updated PFS analysis

MAT-US-2203019-v1.0-04/2022

Kd=carfilzomib and dexamethasone; PFS=progression-free survival.

MAT-US-2203019-v1.0-04/2022

Printed From:

For US Healthcare Professionals Only

Full Prescribing Information Important Safety Information Link to Patient Site

MECHANISM OF ACTION

SARCLISA Is a
Multimodal Anti-CD38 Monoclonal Antibody

SARCLISA Is a Multimodal Anti-CD38 Monoclonal Antibody

Targeted binding to a specific epitope
induces distinct antitumor activity^1-3

Directly destroys

myeloma cells through apoptosis without the need for crosslinking

inhibits

CD38 enzymatic activity
through suppression of the
CD38 ectoenzyme

triggers

cancer cell death through tumor cell targeting, including ADCC, ADCP, and CDC

Enhances

immune cell function through NK cell activation and a decrease in immunosuppressors

Directly destroys

myeloma cells through apoptosis without the need for crosslinking

inhibits

CD38 enzymatic activity
through suppression of the
CD38 ectoenzyme

triggers

cancer cell death through tumor cell targeting, including ADCC, ADCP, and CDC

Enhances

immune cell function through NK cell activation and a decrease in immunosuppressors

CareASSIST Patient Support

SARCLISA Is a
Multimodal Anti-CD38 Monoclonal Antibody

SARCLISA Is a Multimodal Anti-CD38 Monoclonal Antibody

Targeted binding to a specific epitope
induces distinct antitumor activity^1-3

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

SARCLISA Is a Multimodal Anti-CD38 Monoclonal Antibody

SARCLISA Is a Multimodal Anti-CD38 Monoclonal Antibody

Targeted binding to a specific epitope induces distinct antitumor activity1-3

SARCLISA Is a
Multimodal Anti-CD38 Monoclonal Antibody

Targeted binding to a specific epitope
induces distinct antitumor activity^1-3